Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.38 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | FURIN | P09958 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16168173 | 0.94 | TNK2 (0.43) | BTKTNK2NPC1RAB9A | |
| SCHEMBL18800874 | 0.85 | HTT (0.46) | BTKTNK2NPC1RAB9AF10 | |
| SCHEMBL18800753 | 0.79 | BTK (0.49) | BTKSCN9ATNK2 | |
| SCHEMBL18800745 | 0.78 | BTK (0.43) | BTKSCN9ATNK2NPC1RAB9A | |
| SCHEMBL18800635 | 0.78 | BTK (0.48) | BTKSCN9ATNK2 | |
| SCHEMBL18800795 | 0.78 | BTK (0.43) | BTKSCN9ATNK2NUDT14NUDT5 | |
| SCHEMBL18800492 | 0.78 | BTK (0.48) | BTKSCN9ATNK2 | |
| SCHEMBL18800616 | 0.77 | BTK (0.47) | BTKSCN9ATNK2 | |
| SCHEMBL18800564 | 0.76 | BTK (0.47) | BTKSCN9ATNK2NPC1RAB9A | |
| SCHEMBL18800471 | 0.76 | TNK2 (0.40) | BTKSCN9ATNK2NUDT14NUDT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789615-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |